Post Excision/Mohs Scar Laser Resurfacing

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the potential benefits of treating a surgical scar post excision with an ablative fractionated CO2 laser with the goal of decreasing the appearance and size of the scar.

Clinical Trial Description

The objective of this research is to determine, through a split scar study, that treating a post excision scar with a fractionated ablative CO2 laser improves both the texture and cosmetic appearance of the scar. An attempt will be made to determine the ideal timing for treating the excision scar as previous studies have ranged from treating the day of the excision up till 10 weeks post-excision. In order to evaluate the treated portion versus untreated portion of the scar, investigators and the subjects will use a quartile rating scale. In addition, punch biopsy samples will be taken to quantify the difference in collagen architecture 9 weeks after treatment with the laser. There will be a total of 7 study visits to include the day of the excision and laser treatment if randomized to this group, post-op day number 14 for suture removal as well as laser therapy if the subject has been randomized to that treatment group, 4 weeks post-op, 9 weeks post-op and laser treatment for subjects randomized to this time frame for treatment, 12 weeks post-op, 17 weeks post-op and 24 weeks post-op. Each visit will last approximately 30-45 minutes each in which clinical photos of the surgical scar will be taken and any wound care or side effects of the laser therapy or surgery will be addressed. Healing and scar appearance will be reviewed and rated at each of the six postsurgical visits. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02130297
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Completed
Phase	N/A
Start date	May 2014
Completion date	March 19, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02721459` - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma	Phase 1
Completed	`NCT03740815` - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection	N/A
Recruiting	`NCT05779423` - Cryoablation+Ipilimumab+Nivolumab in Melanoma	Phase 2
Terminated	`NCT01468818` - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma	Phase 2
Completed	`NCT01820234` - Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event	N/A
Completed	`NCT00535769` - Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use	Phase 0
Completed	`NCT00526032` - Melanoma Detection by Oblique-Incidence Optical Spectroscopy	N/A
Completed	`NCT00588341` - Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection	Phase 2
Active, not recruiting	`NCT01447199` - The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
Enrolling by invitation	`NCT04758988` - AI Augmented Training for Skin Specialists	N/A
Not yet recruiting	`NCT04534868` - Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area	N/A
Recruiting	`NCT04138342` - Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer	Phase 1
Completed	`NCT03673917` - Cosmetology Students and Skin Cancer	N/A
Recruiting	`NCT04341064` - Sun-safe Habits Intervention and Education	Phase 3
Completed	`NCT04206995` - Cancer Sensing: Evaluation of Odour Sampling Techniques
Recruiting	`NCT05574101` - A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer	Phase 2
Not yet recruiting	`NCT05860881` - Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)	Phase 3
Completed	`NCT05146622` - Virtual Sun Safe Workplaces Ph I
Recruiting	`NCT05068310` - Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
Recruiting	`NCT03889899` - Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.	N/A